

Patient Name	:		Bill Date	:	
DOB/Age/Gender	:		Sample Collected	:	
Patient ID / UHID	:		Sample Received	:	
Referred By	:		Report Date	:	
Sample Type	:		Report Status	:	
Barcode No	:				

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY REPORT
CYFRA 21-1 (Lung Cancer Marker)

Cyfra 21.1	0.754	ng/mL	<3.3
Method : ECLIA			

Interpretation:

Clinical Use :

1. Monitoring the course of Non-small cell lung cancer (NSCLC)
2. Course monitoring in Myoinvasive Bladder cancer

Increased levels :

Non - Small cell carcinoma lung , Acute pneumonia , Tuberculosis , Interstitial lung disease , Liver cirrhosis and Renal failure.

Note :

1. This test is not recommended for the primary diagnosis of Lung cancer.
2. In diagnosed cases of NSCLC, post treatment baseline Sample should be followed by serial determinations at monthly intervals for assessing prognosos
3. In patient receiving Biotin therapy, test should be performed after a minimum period of 8 hours.

Patients on Biotin supplement may have interference in some immunoassays. With individuals taking high dose Biotin (more than 5 mg per day) supplements, at least 8-hour wait time before blood draw is recommended.



Sohini Sengupta

Dr. Sohini Sengupta
MD (Cl Biochemistry), DNB,
FNB (Lab Medicine)
Medical Laboratory Director
HOD (Biochemistry & Special Assays)

Booking Centre :- Sparsh Perfect Diagnostics, .
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.